Exclusive Summary

• Bumetanide Injection, a WHO essential medicine and widely recommended loop diuretic, has a clear and stable global market demand for treating various edematous conditions like heart failure and hypertension.
• Original patents have expired, leading to a competitive yet mature generics market where Chinese suppliers, with bioequivalence approval and in-house API production, can offer high-quality, cost-effective products.
• The product maintains indispensable clinical value in managing acute edema and critical patients, especially those unresponsive to Furosemide.
• Its inclusion in China's Class B medical insurance and bioequivalence approval attest to its market access potential and quality standards.
• As a mature generic, it's well-suited for distribution partnerships, enabling quick market penetration for overseas drug companies.

Asset Materials

Contact Us for Full Materials